Breaking News

UCB, biOasis In Research Pact

December 3, 2012

To use Transcend technology for drug delivery to the brain

biOasis Technologies and UCB, based in Brussels, have entered into a research collaboration to evaluate biOasis’ Transcend technology for the delivery of therapeutic compounds to the brain. biOasis will conduct certain experiments using its Transcend technology as it relates to the delivery of therapeutic compounds owned by UCB for CNS disorders. Financial Terms were not disclosed.
 
"UCB is a highly respected biopharmaceutical company with a broad global presence and a deep pipeline. We’re very pleased to be commencing this collaboration with UCB whom we believe have some tremendous targets for our Transcend vector," said Rob Hutchison, chief executive officer, biOasis Technologies. "The interest from within the industry on our Transcend technology is clearly widening and this agreement with UCB is a prime example of that. The work will start over the next few months and carry into the New Year. We are looking forward to working with the UCB scientists to successfully achieve the objectives we have set out in agreement."
 

Related Contract Manufacturing:

blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent